Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905527 · ClinicalTrials.gov registry record
Adherence Trial With MS LifeLines ® Services
A clinical trial, sponsored by EMD Serono.
- Terminated
- Registry status
- 306
- Enrollment target
NCT01905527 is a clinical trial that was terminated before completion, run by EMD Serono. The registered enrollment target is 306 participants.
The verdict
NCT01905527 was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- 306 participants
- Enrollment target
Study Summary
This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication adherence and treatment persistence with Rebif ® subcutaneous three times a week.
Interventions
- OTHER Group B
- OTHER Standard Services of Group A (Group A1)
- OTHER Customized Services of Group A (Group A2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01905527
The ClinicalTrials.gov registry entry for NCT01905527 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Group B is the first listed.
NCT01905527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01905527 about?
NCT01905527 is a clinical study titled "Adherence Trial With MS LifeLines ® Services". This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication adherence and treatment persistence with Rebif ® subcutaneous three times a ...
What is the current status of trial NCT01905527?
This trial is currently terminated. The enrollment target is 306 participants. The study started on 2013-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01905527?
The interventions under investigation include: Group B (OTHER), Standard Services of Group A (Group A1) (OTHER), Customized Services of Group A (Group A2) (OTHER).
Who is sponsoring clinical trial NCT01905527?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.